This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignees: Guangzhou Yunyuan Biotech Co., Ltd., Hefei Tairui Biotechnology Co., Ltd.. Active years: 2013-2015.
Company Filing History:
2 out of 2 
1 out of 1 Years Active: 2013-2015
Title: Yanwen Jin: Innovator in Biotechnology
Introduction
Yanwen Jin is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 3 patents, his work has the potential to impact cancer treatment and therapeutic applications.
Latest Patents
Yanwen Jin's latest patents include the "Humanized anti-EGFR antibody L4-H3 and coding gene thereof." This patent discloses a humanized anti-EGFR antibody, which consists of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is detailed in positions 1-145 of SEQ ID NO: 3, while the heavy chain constant region corresponds to the human antibody IgG1. The light chain's amino acid sequence is represented as SEQ ID NO: 1. Another significant patent is "Anti-epidermal growth factor receptor antibodies and uses thereof." This invention reveals humanized anti-epidermal growth factor receptor antibodies that exhibit favorable binding activity, with a binding affinity of 6.13×10 mol/L. These antibodies are capable of inhibiting the growth and migration of tumor cells, along with their preparation methods and applications.
Career Highlights
Throughout his career, Yanwen Jin has worked with notable companies in the biotechnology sector, including Guangzhou Yunyuan Biotech Co., Ltd. and Hefei Tairui Biotechnology Co., Ltd. His expertise in antibody development has positioned him as a key figure in advancing therapeutic solutions.
Collaborations
Yanwen Jin has collaborated with esteemed colleagues such as Cheng Cao and Michael Rynkiewicz. These partnerships have further enhanced his research and development efforts in the field of biotechnology.
Conclusion
Yanwen Jin's innovative work in the development of humanized antibodies showcases his commitment to advancing medical science. His contributions have the potential to lead to significant breakthroughs in cancer treatment and therapeutic applications.